This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Suju Luo
Tianjin Medical University General Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Matrix metalloproteinase 13 (MMP13) is a zinc-containing endopeptidase secreted by keratinocytes and skin fibroblasts and participates in many inflammatory diseases. Drugs for retinoic acid include tazarotene and acitretin. Tazarotene/acitretin and narrow-band ultraviolet B (NB-UVB) irradiation are used as a general treatment for psoriasis. However, their impact on MMP13 expression has yet to be determined. In this study, we measured the expression of MMP13 in patients with psoriasis, and investigated the effects of tazarotene and/or NB-UVB on MMP13 expression in a mouse model of psoriasis. After exposure to acitretin and/or NB-UVB, immortalized human HaCaT keratinocytes were analyzed for viability and MMP13 expression. Our results showed that MMP13 protein levels increased in skin lesions and serum samples in patients with psoriasis. Treatment with acitretin and NB-UVB irradiation alone or in combination suppressed cell viability and MMP13 expression in HaCaT cells. Consistently, tazarotene treatment and/or NB-UVB irradiation attenuated imiquimod-induced psoriasis-like dermatitis and inhibited MMP13 expression in a mouse model. Taken together, these results indicate that tazarotene/acitretin and NB-UVB irradiation can inhibit the expression of MMP13 in keratinocytes and psoriasis mouse models. Targeting MMP13 may represent a promising therapeutic strategy against psoriasis.
Keywords
psoriasis retinoic acid tazarotene, acitretin, narrow band ultraviolet B, matrix metalloproteinase 13
Figure 1
Figure 2
Figure 3
This preprint is available for download as a PDF.
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 07 Apr, 2021
Review #4 received
Received 24 Mar, 2021
Review #3 received
Received 24 Mar, 2021
Reviewer #6 agreed
On 18 Mar, 2021
Reviewer #8 agreed
On 18 Mar, 2021
Reviewer #7 agreed
On 18 Mar, 2021
Reviewer #5 agreed
On 18 Mar, 2021
Review #9 received
Received 09 Mar, 2021
Review #14 received
Received 09 Mar, 2021
Review #12 received
Received 09 Mar, 2021
Review #11 received
Received 09 Mar, 2021
Review #1 received
Received 09 Mar, 2021
Review #2 received
Received 09 Mar, 2021
Review #16 received
Received 09 Mar, 2021
Review #10 received
Received 09 Mar, 2021
Review #15 received
Received 09 Mar, 2021
Review #13 received
Received 09 Mar, 2021
Review #8 received
Received 09 Mar, 2021
Reviewer #15 agreed
On 08 Mar, 2021
Reviewer #10 agreed
On 08 Mar, 2021
Reviewer #11 agreed
On 08 Mar, 2021
Reviewer #16 agreed
On 08 Mar, 2021
Reviewer #14 agreed
On 08 Mar, 2021
Reviewer #2 agreed
On 08 Mar, 2021
Reviewer #13 agreed
On 08 Mar, 2021
Reviewer #3 agreed
On 08 Mar, 2021
Reviewer #4 agreed
On 08 Mar, 2021
Reviewer #18 agreed
On 08 Mar, 2021
Reviewer #12 agreed
On 08 Mar, 2021
Reviewer #17 agreed
On 08 Mar, 2021
Reviewer #1 agreed
On 08 Mar, 2021
Reviewers invited
Invitations sent on 06 Mar, 2021
Editor assigned
On 06 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 28 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Suju Luo
Tianjin Medical University General Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 07 Apr, 2021
Review #4 received
Received 24 Mar, 2021
Review #3 received
Received 24 Mar, 2021
Reviewer #6 agreed
On 18 Mar, 2021
Reviewer #8 agreed
On 18 Mar, 2021
Reviewer #7 agreed
On 18 Mar, 2021
Reviewer #5 agreed
On 18 Mar, 2021
Review #9 received
Received 09 Mar, 2021
Review #14 received
Received 09 Mar, 2021
Review #12 received
Received 09 Mar, 2021
Review #11 received
Received 09 Mar, 2021
Review #1 received
Received 09 Mar, 2021
Review #2 received
Received 09 Mar, 2021
Review #16 received
Received 09 Mar, 2021
Review #10 received
Received 09 Mar, 2021
Review #15 received
Received 09 Mar, 2021
Review #13 received
Received 09 Mar, 2021
Review #8 received
Received 09 Mar, 2021
Reviewer #15 agreed
On 08 Mar, 2021
Reviewer #10 agreed
On 08 Mar, 2021
Reviewer #11 agreed
On 08 Mar, 2021
Reviewer #16 agreed
On 08 Mar, 2021
Reviewer #14 agreed
On 08 Mar, 2021
Reviewer #2 agreed
On 08 Mar, 2021
Reviewer #13 agreed
On 08 Mar, 2021
Reviewer #3 agreed
On 08 Mar, 2021
Reviewer #4 agreed
On 08 Mar, 2021
Reviewer #18 agreed
On 08 Mar, 2021
Reviewer #12 agreed
On 08 Mar, 2021
Reviewer #17 agreed
On 08 Mar, 2021
Reviewer #1 agreed
On 08 Mar, 2021
Reviewers invited
Invitations sent on 06 Mar, 2021
Editor assigned
On 06 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 28 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Matrix metalloproteinase 13 (MMP13) is a zinc-containing endopeptidase secreted by keratinocytes and skin fibroblasts and participates in many inflammatory diseases. Drugs for retinoic acid include tazarotene and acitretin. Tazarotene/acitretin and narrow-band ultraviolet B (NB-UVB) irradiation are used as a general treatment for psoriasis. However, their impact on MMP13 expression has yet to be determined. In this study, we measured the expression of MMP13 in patients with psoriasis, and investigated the effects of tazarotene and/or NB-UVB on MMP13 expression in a mouse model of psoriasis. After exposure to acitretin and/or NB-UVB, immortalized human HaCaT keratinocytes were analyzed for viability and MMP13 expression. Our results showed that MMP13 protein levels increased in skin lesions and serum samples in patients with psoriasis. Treatment with acitretin and NB-UVB irradiation alone or in combination suppressed cell viability and MMP13 expression in HaCaT cells. Consistently, tazarotene treatment and/or NB-UVB irradiation attenuated imiquimod-induced psoriasis-like dermatitis and inhibited MMP13 expression in a mouse model. Taken together, these results indicate that tazarotene/acitretin and NB-UVB irradiation can inhibit the expression of MMP13 in keratinocytes and psoriasis mouse models. Targeting MMP13 may represent a promising therapeutic strategy against psoriasis.
Figure 1
Figure 2
Figure 3
This preprint is available for download as a PDF.
Loading...